ClinicalTrials.gg
RecruitingNCT06511765Updated Jun 10, 2026

Anesthetic Block of the Erector Muscles of the Lumbar Spine to Relieve Acute Lumbar Pain: Pilot Study

A Phase 3 interventional study of Ropivacaine and dexamethasone injection solution and Sodium Chloride 0.9% Injection Solution in Lumbago, sponsored by Elsan. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Elsan · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 114 studies in Low Back Pain with a site in France — 30 open to participants now, 33 under way, 5 of them phase 3. Low Back Pain · France.

Planned enrollment
53rd of 79
40 · median 82
Started
2026
with 10 others
Phase 3
10 of 114
4 open now
Primary completion
2026-09
later than 11 of 32 live
Registered
91st of 114
by date

Among the 114 studies in Low Back Pain with a site in France, this one is the 53rd largest by planned enrollment of the 79 interventional ones that give a count, is one of 11 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 11 of the 32 other live ones, and was the 91st registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

30 of the 114 studies in Low Back Pain with a site in France are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Low Back Pain with a site in France, or all of them as a file.
02

Study summary

This study concerns the treatment of recent lumbago and aims to evaluate the efficacy of an anesthetic block of the erector spinae muscles combining ropivacaine and dexamethasone. This treatment is routinely used in several institutions in France, but has never been the subject of a randomized placebo-controlled study to assess its efficacy at D4 of treatment.

The BLOCLOMB comparative, randomized, double-blind study aims to validate the efficacy, over the first 4 days, of anesthetic blocks of the erector spinae muscles, during recent lumbago, on the pain of muscular contractures.

03

Conditions studied

  • Lumbago

Keywords

  • anesthetic blocks
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with lumbago lasting less than 7 days despite analgesic / NSAID treatment.
  2. Patient with NS pain > 6
  3. Patient with Oswestry score > or equal to 30
  4. Patient informed of the trial and having signed the form prior to any trial-specific procedure,
  5. Patient willing and able to undergo all planned examinations and procedures in compliance with the clinical trial protocol,
  6. Patient affiliated to a social security or any health insurance.

Exclusion criteria

Exclusion Criteria:

  1. Presence of "red flag" (non-disc lumbago):

    • Motor deficit or signs of horsetail irritation
    • Inflammatory pain waking up in the 2nd half of the night
    • Tumoral context
    • Infectious context or fever
    • Altered general condition
    • Traumatic context
    • Osteoporotic context
  2. Risk of infection
  3. Patient with poor local skin condition
  4. Patient on AVK or anti-Xa anticoagulation, or bleeding disorder (antiaggregants authorized)
  5. Patients with to Ropivacaine or any of its : Sodium chloride, hydrochloric acid sodium hydroxide
  6. Patient with sciatica
  7. Patient with chronic respiratory insufficiency
  8. Patient with cardiac rhythm disorders
  9. Pregnant or breastfeeding woman or woman refusing effective
  10. Patient deprived of liberty or under legal protection (guardianship or curator)
  11. Patient participating in another clinical research protocol involving a drug or medical device
  12. Patient unable to follow the protocol, as judged by the investigator
  13. Patient refusing to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intravenous injection of Ropivacaine combined with Dexamethasone + usual treatment

    The experimental treatment consists in one single interlaminal injection of 2x20ml Ropivacaine (0.375%) distributed over the L4-L5 (Lumbar vertebrae 4 and 5) and L5-S1 (Lumbar vertebrae 5 and sacrum 1) levels on both sides, combined with 2x4ml Dexamethasone soluble (i.e. 2x1ml). This dose and method of administration are those required for locoregional anesthesia.

    Drug: Ropivacaine and dexamethasone injection solution

  • Placebo comparator
    Intravenous injection of Placebo (sodium chloride 0.9%) + usual treatment

    The placebo treatment consists in one single interlaminal injection of 2x20ml sodium chloride 0.9% distributed over the L4-L5 and L5-S1 levels on both sides.

    Drug: Sodium Chloride 0.9% Injection Solution

Interventions

06

What researchers measure

Primary outcomes

  1. Lumbar pain in activity

    Area under the curve of lumbar pain in activity measured by the patient on a numeric scale (from 0=no pain, and 10=unbearable pain)

    Time frame: At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day2-Day3-Day4. (Hour 0=injection time, Day 1=One day after injection time)

Secondary outcomes

  1. Consumption of concomitant lumbago treatments

    Recording of analgesics and NSAIDs, physiotherapy, manipulations, open surgery, etc

    Time frame: From Day 0 (day of injection) to Day 4

  2. Lumbar pain at rest

    Lumbar pain measured by the patient on a numeric scale

    Time frame: Day 4

  3. Lumbar pain in activity

    Lumbar pain measured by the patient on a numeric scale

    Time frame: Day 4

  4. Lumbar pain at rest

    Area under the curve of lumbar pain at rest measured by the patient on a numeric scale

    Time frame: At Hour 0-Hour1-Hour4-Hour8-Hour12 and Day 1-Day 2-Day 3-Day 4-Day 7-Day 14-Day 21-Day 28

  5. Lumbar Pain < 3

    Percentage of patients with pain \< 3 (measured by the patient on a numeric scale, at rest)

    Time frame: Day 4

  6. Algofunctional index

    Oswestry questionnaire: comprises 10 questions on pain, personal care, load-bearing, walking, sitting, standing, sleep, sex life, social life and travel. Each question offers 6 answers, with a score from 0 to 6, which the patient must choose; a score of 0 corresponds to normal function, and a score of 6 to severely impaired function. The score obtained is multiplied by 2 to obtain a percentage of disability, with 0% for no disability, and 100% for the greatest disability.

    Time frame: Day 0, Day 4 and Day 28

  7. Duration of the interruption of current activities

    Number of days without current activities

    Time frame: 28 days

  8. Duration of the interruption of work

    Number of days of sick leave

    Time frame: 28 days

  9. Complications

    Complications will focus on the following adverse events: 1. injection-site hematoma, nerve damage, limb pain, convulsions, respiratory discomfort, bradycardia, severe vagal malaise 2. fall, iatrogenic infection 3. new lumbago, sciatica or complicated crural neuralgia (neurological deficit, cauda equina syndrome) 4. allergy, digestive complication, renal complication 5. other to be specified

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

Of 35 phase 3 interventional studies under Low Back Pain, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 40. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 22, 2024
StartActual
Mar 24, 2026
Primary completionEst.
Sep 4, 2026
CompletionEst.
Oct 31, 2026
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511765
Lead sponsor
Elsan
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Mar 24, 2026
Primary completion
Sep 4, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Jun 10, 2026

Study contacts

Yves MAUGARS, PhD
Contact
cyhmla@gmail.com
+33 6 44 36 04 00
Vincent WYART
Contact
vincent.wyart@elsan.care

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropivacaine · Dexamethasone

Start the discussion